|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,268.10 INR | +0.86% |
|
-0.19% | +7.39% |
| 06-05 | Lupin Gets US FDA Approval for Ranluspec Interchangeable Biosimilar for Eyesight Ailments | MT |
| 06-04 | Lupin Limited Receives Approval from U.S. FDA for Ranluspec Ranibizumab Injection | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5d. change | Varia. Jan 1. | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| LUPIN LIMITED | Other Pharmaceuticals | +0.86% | -0.19% | +7.39% | +13.45% | +83.87% | 10.88B |  |  |  |
- Stock Market
- Equities
- 500257 Stock
- Charts Lupin Limited
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition